29 completed, 4 terminated, 3 recruiting, 3 unknown. 20 Phase 2, 14 Phase 1, 3 Not applicable, 1 Phase 3, 1 Phase 4.
Follow Nonalcoholic Steatohepatitis (NASH): new trials by email Literature Review of Nonalcoholic Steatohepatitis (NASH) trials Research Report on Nonalcoholic Steatohepatitis (NASH)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Pharmacokinetics and Safety of Miricorilant Miricorilant - Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis | Phase 1 | Completed | Corcept Therapeutics | 14 | 2026-04-30 | 2026-10-16 |
| Evaluation of Miricorilant on Liver Fat in Patients With MASLD Miricorilant - Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 1 | Completed | Corcept Therapeutics | 9 | 2025-08-22 | 2026-09-30 |
| A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor ALN-PNP, Placebo - Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH) | Phase 1 | Completed | Regeneron Pharmaceuticals | 9 | 2024-05-21 | 2025-07-31 |
| To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects IMM-H014, Placebo, IMM-H014 ( FE) - Nonalcoholic Steatohepatitis (NASH) | Phase 1 | Recruiting | Changchun Intellicrown Pharmaceutical Co. LTD | 138 | 2023-12-06 | 2025-04-11 |
| Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH ASC41 2 mg, ASC41 4 mg, Placebo - Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Withdrawn | Gannex Pharma Co., Ltd. | 2023-12-01 | 2024-09-27 | |
| A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) Miricorilant (Cohort A), Placebo (Cohort A), Miricorilant (Cohort B) - Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Completed | Corcept Therapeutics | 175 | 2023-10-25 | 2026-09-29 |
| Study of ADI-PEG 20 Versus Placebo in Subjects With NASH ADI-PEG20, Placebo - Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Recruiting | Polaris Group | 60 | 2023-09-13 | 2025-09-23 |
| A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH) ZSP1601, Placebo - Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Active not recruiting | Guangdong Raynovent Biotech Co., Ltd | 180 | 2023-06-03 | 2025-03-19 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH CS0159 (Linafexor) - Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Completed | Cascade Pharmaceuticals, Inc | 99 | 2023-02-10 | 2023-11-21 |
| HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes HTD1801, Placebo - Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes | Phase 2 | Completed | HighTide Therapeutics (Hong Kong) Limited | 218 | 2022-12-27 | 2026-08-12 |
| A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis Rencofilstat, Placebo - Nonalcoholic Steatohepatitis (NASH), Fibrosis, Liver | Phase 2 | Unknown | Hepion Pharmaceuticals, Inc. | 120 | 2022-10-15 | 2024-05-03 |
| A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH) MRI-PDFF - Nonalcoholic Steatohepatitis (NASH) | Completed | Corcept Therapeutics | 22 | 2022-03-04 | 2024-08-19 | |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH) Miricorilant 150 mg, Miricorilant 100 mg, Miricorilant 50 mg - Nonalcoholic Steatohepatitis (NASH) | Phase 1 | Completed | Corcept Therapeutics | 70 | 2021-11-23 | 2024-08-19 |
| A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension Efimosfermin, Placebo - Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Completed | GlaxoSmithKline | 231 | 2021-09-30 | 2026-07-08 |
| A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects XZP-5610 Tablet (for Part A), Placebo to match XZP-5610 Tablet (for Part A), XZP-5610 Tablet (for Part B) - Nonalcoholic Steatohepatitis (NASH) | Phase 1 | Unknown | Xuanzhu Biopharmaceutical Co., Ltd. | 112 | 2021-05-31 | 2021-06-04 |
| Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH) BMS-986263, Placebo - Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Terminated | Bristol-Myers Squibb | 124 | 2021-03-17 | 2024-09-04 |
| A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH) ORMD-0801 QD - Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Completed | Oramed, Ltd. | 7 | 2021-03-01 | 2024-03-29 |
| Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis Placebo, leronlimab 700 mg, leronlimab 350 mg - Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Completed | CytoDyn, Inc. | 87 | 2020-12-01 | 2023-03-01 |
| Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH) Miricorilant, Placebo - Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Terminated | Corcept Therapeutics | 12 | 2020-11-04 | 2022-08-31 |
| Multiple Dose Safety, Tolerability, PK，PD and Food Effect Study of HEC96719 in Healthy Adult Subjects HEC96719 - Nonalcoholic Steatohepatitis (NASH) | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 66 | 2020-09-14 | 2021-05-07 |
Showing 20 of 42. Sign in to see all of them.
Non-alcoholic Fatty Liver Disease (42) · Fibrosis (4) · Cholangitis, Sclerosing (2) · Hypersensitivity (2) · Liver Cirrhosis (2) · Liver Diseases (2) · Obesity (2) · Acquired Immunodeficiency Syndrome (1) · Coronary Artery Disease (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Fatty Liver (1) · Hepatitis B (1) · Hepatitis C (1) · Overweight (1)
Digestive System Diseases (42) · Fatty Liver (41) · Liver Diseases (40) · Pathological Conditions, Signs and Symptoms (6) · Pathologic Processes (5) · Immune System Diseases (3) · Nutritional and Metabolic Diseases (3) · Bile Duct Diseases (2) · Biliary Tract Diseases (2) · Blood-Borne Infections (2) · Body Weight (2) · Cholangitis (2) · Communicable Diseases (2) · Endocrine System Diseases (2) · Glucose Metabolism Disorders (2)
CORT118335 (3) · firsocostat (3) · Elasticity Imaging Techniques (2) · alpha-Tocopherol (2) · cilofexor (2) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · ADI PEG20 (1) · CRV-431 (1) · Caves (1) · Echocardiography (1) · Electrocardiography (1) · Fenofibrate (1) · Hematologic Tests (1) · Insulin (1) · Magnetic Resonance Imaging (1)
Corcept Therapeutics (6) · Gilead Sciences (6) · Centre hospitalier de l'Université de Montréal (CHUM) (2) · Sunshine Lake Pharma Co., Ltd. (2) · Bristol-Myers Squibb (1) · Cascade Pharmaceuticals, Inc (1) · Changchun Intellicrown Pharmaceutical Co. LTD (1) · ChemomAb Ltd. (1) · CytoDyn, Inc. (1) · Duke University (1) · Forma Therapeutics, Inc. (1) · Galmed Research and Development, Ltd. (1) · Gannex Pharma Co., Ltd. (1) · GlaxoSmithKline (1) · Guangdong Raynovent Biotech Co., Ltd (1)
United States (27) · China (6) · Canada (4) · Puerto Rico (4) · New Zealand (3) · Belgium (2) · France (2) · Germany (2) · Hong Kong (2) · Israel (2) · South Korea (2) · Switzerland (2) · Taiwan (2) · United Kingdom (2) · Argentina (1)
Kavita Juneja, MD (4) · An Tang, MD, MSc (2) · Adrian Di Bisceglie, MD, FACP, FAASLD (1) · Anthony DelConte (1) · Aprille Espinueva, PharmD (1) · Arnon Aharon, MD (1) · Dongyang Liu, Doctor (1) · Edward Doo, MD (1) · Hong Zhang (1) · John S Bomalaski (1)
PMID 25468160, PMID 29333665, PMID 29519502, PMID 29705265, PMID 30059671, PMID 30179269, PMID 30253043, PMID 31278577, PMID 31611038, PMID 31634532, PMID 31965579, PMID 32115759, PMID 32781086, PMID 32794259, PMID 33125080, PMID 33454241, PMID 33682556, PMID 33852720, PMID 33898959, PMID 34006921, PMID 34999207, PMID 36318027, PMID 36368598, PMID 38916482, PMID 39326675, PMID 40434633, PMID 40484014, PMID 41655584
2016 (1), 2019 (1), U01AI115711 (1), U01DK061730 (1)